We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 25, 2021

Clinical Benefit of Treatment After Trastuzumab Emtansine for HER2+ Metastatic Breast Cancer

Breast cancer (Tokyo, Japan)

 

Additional Info

Disclosure statements are available on the authors' profiles:

Breast cancer (Tokyo, Japan)
Clinical Benefit of Treatment After Trastuzumab Emtansine for HER2-Positive Metastatic Breast Cancer: A Real-World Multi-Centre Cohort Study in Japan (WJOG12519B)
Breast Cancer 2021 Jan 02;[EPub Ahead of Print], T Yokoe, S Kurozumi, K Nozawa, Y Ozaki, T Maeda, S Yazaki, M Onishi, A Fujimoto, S Nakayama, Y Tsuboguchi, T Iwasa, H Sakai, M Ogata, M Terada, M Nishimura, T Onoe, J Masuda, M Kurikawa, H Isaka, K Hagio, A Shimomura, Y Okumura, M Futamura, M Shimokawa, T Takano

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading